REG - Fusion Antibodies - Contract win

Fusion AntibodiesAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251008:nRSH4350Ca&default-theme=true

RNS Number : 4350C  Fusion Antibodies PLC  08 October 2025

8 October 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Contract Win

New multi-target Humanisation project with global pharmaceutical company

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that it has been selected to proceed with a new
multi-target Integrated Therapeutic Antibody Services project (the "Project")
with the Antibody Centre of Excellence of a European-based global
pharmaceutical company (the "Client") under a Master Service Agreement ("MSA")
signed earlier in the year. The Project will include humanisation and supply
elements.

 

Humanisation is the process required to make antibodies which were derived
from non-human sequences, typically from mouse or rabbit antibodies, suitable
for use as human therapeutics. Fusion will humanise a family of VHH antibody
fragments for the Client. The Project also involves the expression,
purification and supply of research materials.

 

The selection of Fusion for this Project again demonstrates the Company's
ability to secure contracts with major pharmaceutical businesses. This is seen
as a significant part of the Company's strategy of reducing dependence on more
volatile smaller clients, but also in seeking to exploit the Company's novel
technologies such as OptiMAL®. This will hopefully drive sustainable growth,
strengthen market positioning and open further new commercial opportunities.

 

Work in relation to the Project is expected to be completed within the current
financial year and the Company expects to generate revenues of not less than
£175,000.

 

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to have been selected
to humanise a family of VHH antibody fragments for our Client. It is
particularly gratifying that a client of this magnitude and recognised
expertise, with all the resources available to them, has selected Fusion to
undertake this critical work. It reflects both our position as providers of
world-class antibody engineering services and our ability to deliver
innovative, high-quality solutions for long-lasting partnerships. We look
forward to working with our Client to bring better antibodies to the clinic
more rapidly."

 

Navigate to our Interactive Investor hub here:
https://investorhub.fusionantibodies.com/
(https://investorhub.fusionantibodies.com/) . Engage with us by asking
questions, watching video summaries and seeing what other shareholders have to
say.

 

Enquiries:

 

 Investor questions on this announcement
 We encourage all investors to share questions on this announcement via our      Regulatory news | Fusion Antibodies plc investor hub
 investor hub                                                                    (https://investorhub.fusionantibodies.com/announcements)

 Fusion Antibodies plc                                                                      www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                         Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                      Tel: +44 (0) 207 186 9952

 Walbrook PR                             Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                                 Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 285
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTMRBATMTBMBJA